CN112370365B - Synergistic bactericidal and bacteriostatic ethylhexyl glycerin composition - Google Patents
Synergistic bactericidal and bacteriostatic ethylhexyl glycerin composition Download PDFInfo
- Publication number
- CN112370365B CN112370365B CN202011332530.8A CN202011332530A CN112370365B CN 112370365 B CN112370365 B CN 112370365B CN 202011332530 A CN202011332530 A CN 202011332530A CN 112370365 B CN112370365 B CN 112370365B
- Authority
- CN
- China
- Prior art keywords
- mic
- bacteriostatic
- composition
- evermillid
- ethylhexyl glycerin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 230000003385 bacteriostatic effect Effects 0.000 title claims abstract description 39
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 28
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 229940100524 ethylhexylglycerin Drugs 0.000 title claims abstract description 26
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 24
- 239000002738 chelating agent Substances 0.000 claims abstract description 25
- 150000001413 amino acids Chemical class 0.000 claims abstract description 18
- 239000002537 cosmetic Substances 0.000 claims description 16
- 229940061605 tetrasodium glutamate diacetate Drugs 0.000 claims description 8
- UZVUJVFQFNHRSY-OUTKXMMCSA-J tetrasodium;(2s)-2-[bis(carboxylatomethyl)amino]pentanedioate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CC[C@@H](C([O-])=O)N(CC([O-])=O)CC([O-])=O UZVUJVFQFNHRSY-OUTKXMMCSA-J 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 7
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 7
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 abstract description 4
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 abstract description 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 description 28
- 244000005700 microbiome Species 0.000 description 25
- 239000000126 substance Substances 0.000 description 17
- 239000010445 mica Substances 0.000 description 16
- 229910052618 mica group Inorganic materials 0.000 description 16
- 239000000022 bacteriostatic agent Substances 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 230000002335 preservative effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 241000222122 Candida albicans Species 0.000 description 6
- 229940095731 candida albicans Drugs 0.000 description 6
- 230000000857 drug effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000228245 Aspergillus niger Species 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000003899 bactericide agent Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 238000007599 discharging Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- JDWPDZLCSRBZPY-SQGDDOFFSA-N C(=O)(O)C(C(=O)O)N[C@@H](C)C(=O)O.[Na].[Na].[Na] Chemical compound C(=O)(O)C(C(=O)O)N[C@@H](C)C(=O)O.[Na].[Na].[Na] JDWPDZLCSRBZPY-SQGDDOFFSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282320 Panthera leo Species 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- -1 iron ions Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 229960005323 phenoxyethanol Drugs 0.000 description 3
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 3
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 2
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000191070 Escherichia coli ATCC 8739 Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- YGDANRKJYNQFFR-FBCQKBJTSA-N C[C@@H](O)[C@H](N(CC(O)=O)CC(O)=O)C(O)=O Chemical compound C[C@@H](O)[C@H](N(CC(O)=O)CC(O)=O)C(O)=O YGDANRKJYNQFFR-FBCQKBJTSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- MGIYRDNGCNKGJU-UHFFFAOYSA-N isothiazolinone Chemical compound O=C1C=CSN1 MGIYRDNGCNKGJU-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical class 0.000 description 1
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000012747 synergistic agent Substances 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- OVXKVGHEOJHEJN-WJXVXWFNSA-K trisodium (2S)-2-[bis(carboxylatomethyl)amino]-3-hydroxypropanoate Chemical compound [Na+].[Na+].[Na+].OC[C@H](N(CC([O-])=O)CC([O-])=O)C([O-])=O OVXKVGHEOJHEJN-WJXVXWFNSA-K 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Abstract
The invention discloses a synergistic bactericidal and bacteriostatic ethylhexyl glycerin composition, which is characterized by comprising ethylhexyl glycerin and an amino acid chelating agent, wherein the mass concentration of the ethylhexyl glycerin and the amino acid chelating agent is 1: 64-1: 0.25; the amino acid chelating agent has the following structure, wherein R is CH2，CH2CH2，CH2CH2CH2，CH2CH2CH2CH2，CH2CH2CH2CH2CH2，CH2OCH2Or CH2CH2OCH2CH2；R1，R2Is CH2CH2Or CH2CH2CH2. The composition can greatly improve the efficacy of the composition and exert the synergistic sterilization and bacteriostasis performance.
Description
Technical Field
The invention belongs to the technical field of daily chemical industry, and relates to an antibacterial composition, in particular to a synergistic bactericidal and bacteriostatic ethylhexyl glycerin composition which contains ethylhexyl glycerin and an amino acid chelating agent and shows synergistic bactericidal and bacteriostatic effects.
Background
One trend affecting the global cosmetic industry is the increasing demand for naturally sustainable products and raw materials. This is also true for safe, effective and green preservative systems. Meeting the demand for mild green preservatives while ensuring the efficacy and broad-spectrum antibacterial activity of the preservatives is a serious challenge faced by current preservatives.
At present, the traditional preservative is mainly synthesized chemically. Are at issue because of the safety and irritation associated with long-term use. The most commonly used conventional preservatives at present include: imidazolidinyl urea, hydantoin, isothiazolinone, parabens, quaternary ammonium salt-15, benzoic acid/benzyl alcohol and derivative preservatives, benzoic acid/sodium benzoate/potassium sorbate, brobopol (2-bromo-2-nitro-1, 3-propanediol), IPBC, triclosan and the like. There are different degrees of safety and health risks associated with the use of these preservatives over a long period of time. At the same time, regulations also forbid and limit the amount and field of use of some preservatives, such as methylisothiazolinone, methylchloroisothiazolinone (carbosone), which in chinese regulations limits the maximum permissible concentration to: 0.0015% and can only be used in rinsing products.
The preservative acts on different targets of microorganisms to play the roles of sterilization and bacteriostasis. Depending on the mechanism of action, preservatives can act on cell walls, cell membranes, interfering with the membrane permeability and integrity of microorganisms. It can also act on the activity of enzymes affecting cell metabolism or on the cytoplasmic part of the genetic microparticulate structure to produce effects, such as alcohols and derivatives thereof (e.g. phenoxyethanol). However, long-term use of these preservatives acting on the DNA of specific target proteins and genetic materials increases the possibility of microbial mutation, resulting in microbial resistance. Antimicrobial resistance is a serious challenge facing humans in the 21 st century.
The pursuit of a mild, safe, effective preservative system is a necessary trend. However, mild preservatives also have relatively poor biocidal activity against microorganisms. There is no perfect bactericide which can achieve good sterilization effect on such a wide variety of microorganisms. In cosmetic formulations, a synergistic bacteriostatic effect is often achieved by adding a scientific combination of different ingredients. Therefore, the combination of several preservatives or components with preservative efficacy forms a high-efficiency and broad-spectrum synergistic preservative system, which is a necessary trend for the development of preservatives.
The ethylhexyl glycerin, as a polyalcohol substance, can obviously improve the efficacy of some traditional preservatives, such as parabens and phenoxyethanol, and greatly reduce the using amount of the traditional preservatives under low using amount. Also as deodorants, moisturizers, skin conditioners, and the like, in personal care and cosmetic formulations. Because of its surfactant structure, it interferes with interfacial tension, making some active ingredients or preservatives more accessible to microbial cells. And the integrity of the cell membrane is damaged by changing the surface tension of the cell membrane of the microorganism, and the growth and metabolism of the microorganism cells are interfered, so that the effect of inhibiting the growth of the microorganism is achieved. The ethylhexyl glycerol is not easy to generate drug resistance because of acting on nonspecific targets. With the application of advanced biotechnology, the ethyl hexyl glycerol can be synthesized by a biotechnology mode at present, so that the real green process and the atom economy are realized, and the application of a green preservative system is promoted.
Chelating agents such as EDTA, which is widely used in the washing field and the personal care field, are frequently used in cosmetics to prevent contamination or discoloration of products by combining with metal ions or metal compounds. Meanwhile, the chelating agent can improve the efficacy of some preservatives and antioxidants, and plays an important role in the stability and efficacy of personal skin care products. The chelating agent itself also has an inhibitory effect on the growth of microorganisms. By obtaining metal ions, chelators interfere with the bioavailability of the metal ions, and thus may selectively interfere with the basal metabolism of the microbial cells. Chelators can destroy the activity of certain gram-positive bacteria, such as staphylococcus aureus, biofilms. For some gram-negative bacteria, the maintenance of the biological membrane needs the participation of magnesium, calcium and iron ions. Meanwhile, iron ions are also important components for respiration and metabolism of microorganisms. The chelating agent can effectively inhibit the utilization of iron ions by microorganisms, so that the metabolism in the microorganisms is disturbed, the microorganisms are finally killed, and the broad-spectrum antibacterial property is realized. Meanwhile, the mechanism of action intervenes in the external environment on which the microorganisms live, so that the drug resistance is extremely unlikely to occur.
Disclosure of Invention
The invention provides a synergistic bactericidal and bacteriostatic ethylhexylglycerin composition used in cosmetics, which comprises ethylhexylglycerin and an amino acid chelating agent, has a synergistic effect on the capability of resisting microorganisms, is far greater than the capability of being used alone on resisting microorganisms when the ethylhexylglycerin and the amino acid chelating agent are used in combination, has high safety performance on users, high biodegradability, atomic economy, recyclable economy and the like, and provides a new preservative compound scheme for the field of cosmetics by showing the advantages of human health and environmental sustainable development.
The synergistic bactericidal and bacteriostatic ethylhexyl glycerin composition is characterized by comprising ethylhexyl glycerin and an amino acid chelating agent, wherein the mixture ratio is 1:64 to 1:0.25 by mass concentration; the amino acid chelating agent has the following formula:
or
Wherein R is CH2，CH2CH2，CH2CH2CH2，CH2CH2CH2CH2，CH2CH2CH2CH2CH2，CH2OCH2Or CH2CH2OCH2CH2；R1，R2Is CH2CH2Or CH2CH2CH2。
The ethylhexyl glycerin is generally used as a functional auxiliary of other traditional preservatives in cosmetics, such as a synergist of phenoxyethanol, methylisothiazolinone and the like. Although conventional common bactericidal and bacteriostatic agents in cosmetics, such as parabens and cason, have strong bactericidal and bacteriostatic abilities, reports show that the conventional common bactericidal and bacteriostatic agents have potential risks to human health after long-term use and are easy to generate drug resistance of microorganisms. The composition of the invention contains ethylhexyl glycerin or amino acid chelating agent, which are not listed in a preservative in a cosmetic formula and are not used as active ingredients of a bactericidal bacteriostatic agent. The composition of the invention shows stronger synergistic effect on the sterilization and bacteriostasis performance, and as a sterilization and bacteriostasis composition, on one hand, the combination of the two is mutually enhanced, which can greatly improve the performance of single use in bacteriostasis, and on the other hand, can reduce the use addition of other bacteriostasis bactericides.
The composition adopts the amino acid chelating agent, and the amino acid chelating agent has higher chelating capacity and better biodegradability and is the best substitute of EDTA (ethylene diamine tetraacetic acid) in the traditional petrochemical source in the field of chelating agent application. The amino acid chelating agent and the preparation method thereof can be found in CN 2019102380351.
Preferably, the composition comprises the ethylhexyl glycerol and the amino acid chelating agent in a ratio of 1:16 to 1:2 by mass concentration. Most preferred in the personal care area are 1:4 to 1: 2.
preferably, in said composition, the amino acid chelating agent is selected from tetrasodium glutamate diacetate, trisodium dicarboxymethylalanine, trisodium threonine diacetate, trisodium serine diacetate, and the like.
The invention also relates to the application of the composition as a bactericidal and bacteriostatic active component in cosmetics.
The composition is used as a sterilization bacteriostat of cosmetics, and the addition amount of the composition in a formula is 0.01-5% of ethylhexyl glycerol and 0.05-20% of amino acid chelating agent by mass percent in the formula.
Has the advantages that: aiming at the requirements of a green mild safe preservative system, the invention provides a synergistic bactericidal and bacteriostatic ethylhexyl glycerin composition, which comprises ethylhexyl glycerin and an amino acid chelating agent. As a novel compound combination scheme, the composition can greatly improve the efficacy of the composition and exert the synergistic anticorrosion performance. The composition can replace the traditional bactericide as a safe and green bactericidal bacteriostatic agent and is widely applied to cosmetics.
Drawings
FIG. 1 is a schematic diagram of two substances added to a 96-plate in a concentration gradient.
FIG. 2 EvermillidTMEHG and EvermillidTMGLDA-30 acts on (A) the antibacterial effect and (B) of escherichia coli
An equivalent curve; grey is the non-bacteriostatic concentration combination and blank is the concentration combination that achieves bacteriostatic ability.
FIG. 3 EvermillidTMEHG and EvermildTMGLDA-30 combined action on pseudomonas aeruginosa (A) bacteriostasis effect sum (B)
An equivalent curve.
FIG. 4 EvermillidTMEHG and EvermillidTMGLDA-30 combined effects on (A) bacteriostatic effect and (B) equivalent curve of Staphylococcus aureus.
FIG. 5 EvermillidTMEHG and EvermillidTMGLDA-30 acts on (A) the bacteriostatic effect and (B) the equivalent curve of Candida albicans jointly.
FIG. 6 EvermillidTMEHG and EvermillidTMGLDA-30 combined effects on (A) bacteriostatic effect and (B) equivalent curve of Aspergillus niger.
Detailed Description
The testing method used by the invention adopts a checkerboard micro liquid based dilution method (checkerboard micro dilution assay) and a part bacteriostatic Concentration index FICI (fractional inhibition Concentration index) to determine the synergistic effect of the two bacteriostatic agents. This method is widely used to study interactions between drugs and is the best known, also approved, simple and effective method to verify synergy between two antibiotics. The experiment was conducted in a two-dimensional array of combinations using a series of concentrations of the two test antibiotics to demonstrate that the combined agents are capable of producing a greater inhibitory effect than the sum of the effects alone.
A96-well sterile microplate was used, two bacteriostats, and in the present example, ethylhexylglycerol (Evermiled) synthesized biotechnologically from lion chemistry in the applicant was usedTMEHG) and the amino acid chelator tetrasodium glutamate diacetate (evermil) from lions chemistryTMGLDA-30), dicarboxymethylalanine trisodium, threonine diacetic acid trisodium, serine diacetic acid trisodium, etc., up to two times the MIC concentration, diluted in multiple ratios, and taken at 8-12 dilutions. Then 50. mu.l of each of the cells were placed in rows and columns of a 96-well plate, and 100. mu.l of the bacterial suspension was added to each well to obtain a final inoculum size of 5X 105CFU/ml。
As shown in FIG. 1, columns A1-H1 of the 96-well plate show bacteriostatic ability when bacteriostatic agent B alone without bacteriostatic agent A; and the horizontal rows H1-H11 of the 96-well plate show the bacteriostatic ability of the bacteriostatic agent A alone without adding the bacteriostatic agent B. Columns A12-H12, are blank controls without addition of bacterial suspension.
The cells were incubated overnight in an incubator for 12 hours or more. The next day, the liquid in any well is visibly clear and transparent if the turbid bacterial suspension in any well effectively inhibits the growth of microorganisms after the bacteriostatic agent or the combined bacteriostatic agent is added. If the bacteriostatic agent does not act to inhibit the growth of microorganisms, it remains in the form of a cloudy bacterial suspension. Then, to further confirm that the bacteria inside the clear transparent wells were effectively inhibited, clear transparent wells at the critical point were selected, 100ul of liquid was aspirated from each well, evenly spread on an agar plate, and cultured overnight in an incubator for 12 hours. The next day, no colonies were observed on the agar plates, which was the concentration combination that was effective for inhibition.
The FICI method adopted in the experiment is developed based on the Loewe Adaptability (LA) theory, and the interaction between the tested bacteriostatic agents can be quantified. (Qi cun et al, determining the in vitro anti-aspergillus fumigatus activity of tetrandrine combined with voriconazole by chessboard method, journal of Chinese dermatology, No. 2 in 2014, P108-111) and the formula is
FICI＝MICA Combination of/MICA Alone+MICB Combination of/MICB Alone
MIC in the formulaA AloneAnd MICB AloneMIC, MIC for component A and B alone respectivelyA Combination ofAnd MICB Combination ofThe two substances are combined to reach respective concentrations when the two substances have the same drug effect as the single drug.
When the FICI is less than or equal to 1, the synergistic effect is achieved, and the smaller the FICI is, the stronger the synergistic effect is; when FICI is 1. ltoreq. FICI.ltoreq.4 is an irrelevant effect, and when FICI > 4 is an antagonistic effect (see European Patent Application EP 2138189A 1).
The strains selected by the experiment are selected as the following five strains by referring to preservative challenge experiments (such as CTFA/USP 51/Chinese cosmetic test specification): escherichia coli ATCC8739, Pseudomonas aeruginosa ATCC 9027, Staphylococcus aureus ATCC 6538, Candida albicans ATCC 10231, Aspergillus niger ATCC 16404.
Using the agar dilution method, two bacteriostatic agents (in the following examples of the invention, ethylhexyl glycerol and tetrasodium glutamate diacetate, Evermillid, respectively) were tested separatelyTMEHG and EvermillidTMGLDA-30, illustrates the synergistic effect of the compositions of the present invention on their antimicrobial capabilities. ) Minimum Inhibitory Concentration (MIC) against different microorganisms.
TABLE 1 MIC values
According to the MIC value obtained by testing and the common concentrations of the two components in the practical application of the formula, Evermiled is respectively selected for testing the concentrations of the two componentsTMThe EHG was gradually diluted to 2000,1000,500, 250, 125, 64,32,16,8,0 (units ug/ml) starting at 4000 ug/ml. EvermillidTMGLDA-30 was diluted stepwise starting from 32,000ug/ml (active concentration) to a weight addition of 16000, 8000,4000,2000,1000,500, 0.
All laboratory strains were stored strictly according to the operating specifications, with passages not exceeding 5 generations.
The experimental results can be expressed as a bacteriostatic result graph and an isobologram. Among them, the experimental result graph is shown, which represents the growth of microorganisms in a 96-well plate. The grey-lined micropores indicate that the two test substances added do not effectively inhibit the growth of microorganisms. And no micropores for the continuous growth of microorganisms are marked by white, which shows that the added two substances to be detected can effectively inhibit the growth of microorganisms and play a role in bacteriostasis and sterilization.
The curves were subjected to Isobolograms (Isobolograms) to verify the correlation between the two. And drawing the MIC values of the two medicines when the two medicines are used together by an isobologram method. The shape of the equivalent curve can be used for judging different effects of synergy (concave), antagonism (convex), independence (straight line) and the like.
Example 1: escherichia coli ATCC8739
1. In a 96-well plate, two components were added at different concentrations, and the results of inhibition of escherichia coli are shown in fig. 2A. The gray circles in the figure indicate that the composition remains cloudy after addition of the composition, indicating no bacteriostatic ability. The open white circles in the figure indicate that the addition of the components has effectively inhibited the growth of bacteria and the suspension of bacteria is clear from turbidity.
2. Calculating the FICI of part of the bacteriostatic indexes and calculating the adding proportion of the two components.
Component A is EvermillidTMEHG(MICA) The concentration was calculated in ppm (ug/ml),
component B is EvermillidTMGLDA-30(MICB) The concentration was calculated in ppm (ug/ml).
Calculated as 100% active, the results are given in table 2 below.
FICI＝MICA Combination of/MICA Alone+MICB Combination of/MICB Alone
In the formula, MICA AloneAnd MICB AloneMIC, MIC for component A and B alone respectivelyA Combination ofAnd MICB Combination ofThe two substances are combined to reach respective concentrations when the two substances have the same drug effect as the single drug.
Concentration ratio of A/B active: a and B are added in the ratio calculated by the concentration of the active substance (ppm).
TABLE 2
Wherein the superscript isaThe identified fractions, all with FICI values less than 0.5, have a significant synergistic relationship.
3. An equivalent curve. Wherein EvermildTMEHG and EvermillidTMGLDA-30 is calculated according to the weight percentage of the product. Calculated as 0.1% (w/w) per 1000ppm active. Wherein, EvermillidTMGLDA-30 was calculated at an active concentration of 30%.
EvermildTMEHG and EvermillidTMThe equivalent curve of the GLDA-30 combination on E.coli is shown in FIG. 2B.
In conclusion, Evermillid for E.coliTMEHG and EvermillidTMThe preferred ratio of the two components of GLDA-30 is 1:16 to 1: 1. The more preferable composition has a bacteriostatic index FICI of 0.25, which shows that the two have strong synergistic effect.
Example 2: pseudomonas aeruginosa ATCC 9027
The two components were added at different concentrations in a 96-well plate, and the results of bacteriostasis on pseudomonas aeruginosa are shown in fig. 3A. The gray circles in the figure indicate that the composition remains cloudy after addition of the composition, indicating no bacteriostatic ability. The open white circles in the figure indicate that the addition of the components has effectively inhibited the growth of bacteria and the suspension of bacteria is clear from turbidity.
1. Calculating the FICI of part of the bacteriostatic indexes and calculating the adding proportion of the two components.
Component A is EvermillidTMEHG(MICA) The concentration was calculated in ppm (ug/ml),
component B is EvermillidTMGLDA-30(MICB) The concentration was calculated in ppm (ug/ml). Calculated as 100% active, the results are given in table 3 below.
FICI＝MICA Combination of/MICA Alone+MICB Combination of/MICB Alone
In the formula, MICA AloneAnd MICB AloneMIC, MIC for component A and B alone respectivelyA Combination ofAnd MICB Combination ofThe two substances are combined to reach respective concentrations when the two substances have the same drug effect as the single drug.
Concentration ratio of A/B active: a and B are added in the ratio calculated by the concentration of the active substance (ppm).
TABLE 3
Wherein the superscript isaThe identified fractions, all with FICI values less than 0.5, have a significant synergistic relationship.
2. An equivalent curve. Wherein EvermillidTMEHG and EvermillidTMGLDA-30 is calculated according to the weight percentage of the product. Calculated as 0.1% (w/w) per 1000ppm active. Wherein, EvermillidTMGLDA-30 was calculated at an active concentration of 30%.
EvermildTMEHG and EvermillidTMThe equivalent curve of GLDA-30 in combination on Pseudomonas aeruginosa is shown in FIG. 3B.
In summary, Evermillid for Pseudomonas aeruginosaTMEHG and EvermillidTMThe preferred effective ratio of the two components of GLDA-30 is 1:16 to 1: 2. The more preferable composition has a bacteriostatic index FICI of 0.25, which shows that the two have strong synergistic effect.
Example 3: staphylococcus aureus ATCC 6538
1. In a 96-well plate, two components are added according to different concentrations, and the bacteriostatic result on staphylococcus aureus is shown in fig. 4A. The gray circles in the figure indicate that the composition remains cloudy after addition of the composition, indicating no bacteriostatic ability. The open white circles in the figure indicate that the addition of the components has effectively inhibited the growth of bacteria and the suspension of bacteria is clear from turbidity.
2. Calculating the FICI of part of the bacteriostatic indexes and calculating the adding proportion of the two components.
Component A is EvermillidTMEHG(MICA) The concentration was calculated in ppm (ug/ml),
component B is EvermillidTMGLDA-30(MICB) The concentration was calculated in ppm (ug/ml).
Calculated as 100% active, the results are given in table 4 below.
FICI＝MICA Combination of/MICA Alone+MICB Combination of/MICB Alone
In the formula, MICA AloneAnd MICB AloneMIC, MIC for component A and B alone respectivelyA Combination ofAnd MICB Combination ofThe two substances are combined to reach respective concentrations when the two substances have the same drug effect as the single drug.
Concentration ratio of A/B active: a and B are added in the ratio calculated by the concentration of the active substance (ppm).
TABLE 4
Wherein the superscript isaThe identified fractions, all with FICI values less than 0.5, have a significant synergistic relationship.
3. An equivalent curve. Wherein EvermillidTMEHG and EvermillidTMGLDA-30 is calculated according to the weight percentage of the product. Calculated as 0.1% (w/w) per 1000ppm active. Wherein, EvermillidTMGLDA-30 was calculated at an active concentration of 30%.
EvermildTMEHG and EvermillidTMThe equivalent curve of the combination of GLDA-30 on Staphylococcus aureus is shown in FIG. 4B.
In summary, for Staphylococcus aureus, everMilldTMEHG and EvermillidTMThe preferred ratio of the two components of GLDA-30 is 1:16 to 1: 2. The more preferable composition has a bacteriostatic index FICI of 0.31, which shows that the two have strong synergistic effect.
Example 4: candida albicans ATCC 10231
1. The two components were added at different concentrations in a 96-well plate, and the bacteriostatic results for candida albicans are shown in fig. 5A. The gray circles in the figure indicate that the composition remains cloudy after addition of the composition, indicating no bacteriostatic ability. The open white circles in the figure indicate that the addition of the components has effectively inhibited the growth of bacteria and the suspension of bacteria is clear from turbidity.
2. Calculating the FICI of part of the bacteriostatic indexes and calculating the adding proportion of the two components.
Component A is EvermillidTMEHG(MICA) The concentration was calculated in ppm (ug/ml),
component B is EvermillidTMGLDA-30(MICB) The concentration was calculated in ppm (ug/ml).
Calculated as 100% active, the results are given in table 5 below.
FICI＝MICA Combination of/MICA Alone+MICB Combination of/MICB Alone
In the formula, MICA AloneAnd MICB AloneMIC, MIC for component A and B alone respectivelyA Combination ofAnd MICB Combination ofThe two substances are combined to reach respective concentrations when the two substances have the same drug effect as the single drug.
Concentration ratio of A/B active: a and B are added in the ratio calculated by the concentration of the active substance (ppm).
TABLE 5
The FICI values of the parts marked by the superscript a are all less than 0.5, and the significant synergistic relationship is realized.
3. An equivalent curve. Wherein EvermillidTMGLDA-30 and EvermillidTMThe EHGs are calculated as weight percent of their products, respectively. Calculated as 0.1% (w/w) per 1000ppm active. Wherein, EvermillidTMGLDA-30 was calculated at an active concentration of 30%.
EvermildTMGLDA-30 and EvermillidTMThe equivalent curve of the combination of EHG on Candida albicans is shown in FIG. 5B.
In summary, for Candida albicans, EvermiledTMEHG and EvermillidTMThe preferable proportion of the two components of GLDA-30 is 2: 1. the more preferred composition has a bacteriostatic index FICI of 0.38, which shows strong synergy.
Example 5: aspergillus niger ATCC 16404
1. In a 96-well plate, two components were added at different concentrations, and the results of bacteriostasis on aspergillus niger are shown in fig. 6A. The gray circles in the figure indicate that the composition remains cloudy after addition of the composition, indicating no bacteriostatic ability. The open white circles in the figure indicate that the addition of the components has effectively inhibited the growth of bacteria and the suspension of bacteria is clear from turbidity.
2. Calculating the FICI of part of the bacteriostatic indexes and calculating the adding proportion of the two components.
Component A is EvermillidTMEHG(MICA) The concentration was calculated in ppm (ug/ml),
component B is EvermillidTMGLDA-30(MICB) The concentration was calculated in ppm (ug/ml). Calculated as 100% active, the results are given in table 6 below.
FICI＝MICA Combination of/MICA Alone+MICB Combination of/MICB Alone
In the formula, MICA AloneAnd MICB AloneMIC, MIC for component A and B alone respectivelyA Combination ofAnd MICB Combination ofThe two substances are combined to reach respective concentrations when the two substances have the same drug effect as the single drug.
Concentration ratio of A/B active: a and B are added in the ratio calculated by the concentration of the active substance (ppm).
TABLE 6
Wherein the superscript isaThe identified fractions, all with FICI values less than 0.5, have a significant synergistic relationship.
3. An equivalent curve. Wherein EvermillidTMGLDA-30 and EvermillidTMEHG according to it respectivelyCalculating the weight percentage of the product. Calculated as 0.1% (w/w) per 1000ppm active. Wherein, EvermillidTMGLDA-30 was calculated at an active concentration of 30%.
EvermildTMGLDA-30 and EvermillidTMThe equivalent curve of EHG in combination with Aspergillus niger is shown in FIG. 6B.
In conclusion, Evermiled for Aspergillus nigerTMEHG and EvermillidTMThe preferred ratio of the two components of GLDA-30 is 1:64 to 1: 4. The more preferable composition has a bacteriostatic index FICI of 0.28, which shows that the two have strong synergistic effect.
Example 6
Evermiled is respectively used for the creamTMGLDA-30，EvermildTMChallenge experiments with microorganisms were performed with both EHG and the combination. The experimental data are as follows:
as can be seen from the table: the antiseptic and bactericidal capacity of the product can be obviously improved by adding the combined composition. Microbial challenge experiments that appeared to be against bacterial fungi passed the international CTFA standard.
The Evermillid is added in the formulaTMGLDA-30 and EvermillidTMThe EHG composition obviously improves the preservation characteristics of the product to microorganisms, particularly shows on bacteria and saccharomycetes, and can obviously enhance the preservation.
As an antiseptic synergistic agent of cosmetics, the additive amount in the formula is as follows according to the mass percentage in the formula: 0.01-5% of ethylhexyl glycerol (component A) and 0.05-20% of tetrasodium glutamate diacetate or trisodium dicarboxymethylalanine (component B). Several examples of formulations are listed below for illustration.
Example 7: hair shampoo
The operation process comprises the following steps: 1. sequentially adding the phase A components into a reaction kettle; stirring evenly 2, adding the phase B while stirring until the phase B is even; 3. adding phase C to adjust pH. 4. Heat to 85 ℃ while stirring until the system is clear. 5. Cooling to 40 ℃, and discharging.
Example 8: shower gel
The operation process comprises the following steps:
1. heating phase A to 85 deg.C, and stirring to uniform; 2. cooling to 70 ℃, adding the phase B while stirring until the phase B is uniform; 3. cooling to room temperature, adding C, D phase while stirring until uniform; 4. adding phase E to regulate pH value and discharging.
Example 9: toning lotion
The operation process comprises the following steps:
and sequentially adding the phase A component into the reaction kettle, and uniformly stirring at 85 ℃. After cooling to normal temperature, the pH value is adjusted to 6.6, and discharging is carried out.
Example 10: wet tissue
The operation process comprises the following steps:
and sequentially adding the phase A component into the reaction kettle, and uniformly stirring at 50 ℃. Cooling to normal temperature, adjusting pH to 5.8-6.0, and discharging.
Claims (5)
1. The synergistic bactericidal and bacteriostatic ethylhexyl glycerin composition is characterized by consisting of ethylhexyl glycerin and an amino acid chelating agent of tetrasodium glutamate diacetate, wherein the mass concentration of the composition is 1:64 to 1: 0.25.
2. The ethylhexyl glycerin composition as claimed in claim 1, wherein the ratio of ethylhexyl glycerin to tetrasodium glutamate diacetate in the composition is 1:16 to 1:2 by mass concentration.
3. The ethylhexyl glycerin composition as claimed in claim 2, wherein the ratio of ethylhexyl glycerin to tetrasodium glutamate diacetate in the composition is 1:4 to 1:2 by mass concentration.
4. Use of the ethylhexyl glycerin composition according to claim 1 as a bactericidal and bacteriostatic active ingredient in cosmetics.
5. The use according to claim 4, wherein the ethylhexyl glycerin composition is added in a cosmetic formulation in an amount of 0.01 to 5% by mass of ethylhexyl glycerin and 0.05 to 20% by mass of tetrasodium glutamate diacetate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011332530.8A CN112370365B (en) | 2020-11-24 | 2020-11-24 | Synergistic bactericidal and bacteriostatic ethylhexyl glycerin composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011332530.8A CN112370365B (en) | 2020-11-24 | 2020-11-24 | Synergistic bactericidal and bacteriostatic ethylhexyl glycerin composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112370365A CN112370365A (en) | 2021-02-19 |
| CN112370365B true CN112370365B (en) | 2022-04-29 |
Family
ID=74588042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011332530.8A Active CN112370365B (en) | 2020-11-24 | 2020-11-24 | Synergistic bactericidal and bacteriostatic ethylhexyl glycerin composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112370365B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113854294A (en) * | 2021-10-26 | 2021-12-31 | 陕西省动物研究所 | Disinfectant composition for musk deer breeding houses as well as preparation method and application of disinfectant composition |
| FR3137290A1 (en) * | 2022-06-30 | 2024-01-05 | L'oreal | Conservative system and associated composition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111000789A (en) * | 2019-12-24 | 2020-04-14 | 拉芳家化股份有限公司 | Cosmetic composition containing omega-3 anti-aging active matter |
| CN111632008A (en) * | 2020-06-17 | 2020-09-08 | 凯娜黛莎化妆品有限公司 | CBD hemp essence emulsion and preparation method thereof |
-
2020
- 2020-11-24 CN CN202011332530.8A patent/CN112370365B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111000789A (en) * | 2019-12-24 | 2020-04-14 | 拉芳家化股份有限公司 | Cosmetic composition containing omega-3 anti-aging active matter |
| CN111632008A (en) * | 2020-06-17 | 2020-09-08 | 凯娜黛莎化妆品有限公司 | CBD hemp essence emulsion and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112370365A (en) | 2021-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210337835A1 (en) | Composition containing glycolipids and preservatives | |
| EP2387883B2 (en) | Antimicrobial compositions comprising sodium benzoate | |
| KR101211389B1 (en) | Broad spectrum preservation blends | |
| US20080311231A1 (en) | Broad Spectrum Non-Traditional Preservative System | |
| CN112370365B (en) | Synergistic bactericidal and bacteriostatic ethylhexyl glycerin composition | |
| MX2012002083A (en) | Broad spectrum preservation blends. | |
| EP2296614A2 (en) | Synergistic preservative blends | |
| KR102272901B1 (en) | Composition for external application to the skin containing meso-2,3-butanediol as a preservative | |
| CN110934759B (en) | Application of cocamidopropyl PG-dimethyl ammonium chloride as bacteriostatic agent and application of cocamidopropyl PG-dimethyl ammonium chloride as bacteriostatic agent in daily chemical products | |
| AU2014301021B2 (en) | Synergistic preservative blends | |
| JP2020164548A (en) | Composition containing meso-2,3-butanediol | |
| JP4091559B2 (en) | Antiseptic disinfectant and cosmetics, pharmaceuticals and foods containing the antiseptic disinfectant | |
| JP4681041B2 (en) | An isothiazolone-containing preservative with improved efficacy. | |
| EP1883401B1 (en) | Anti-microbial agent | |
| KR20150050234A (en) | Composition containing octyl gallate | |
| KR101788179B1 (en) | Low irritation skin external application composition with an improved antiseptic ability | |
| US8362077B2 (en) | Chemical compositions for skin care emulsions and heavy duty hand cleansers | |
| CN108403460A (en) | One kind containing decoyl hydroximic acid and PVP-H2O2Compositional antiseptic agent and preparation method thereof | |
| KR102260163B1 (en) | Antimicrobial Cosmetic Composition | |
| CN111000743B (en) | Cocoamidopropyl PG-dimethyl ammonium chloride and polyalcohol compound and application thereof | |
| JP2007145748A (en) | Antiseptic sterilizer, cosmetic or medicine containing the antiseptic sterilizer, and method for antiseptic sterilization | |
| KR20200145782A (en) | A preservative for skin external application, and a cosmetic composition and a pharmaceutical composition comprising the same | |
| JP4587673B2 (en) | Cleaning composition | |
| CN108498399B (en) | Compound plant extract with antiseptic effect and application thereof in cosmetic antiseptic | |
| KR102189174B1 (en) | Composition of antibacterial agent containing industrial preservatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A synergistic bactericidal and antibacterial ethylhexyl glycerol combination Granted publication date: 20220429 Pledgee: Zijin Branch of Nanjing Bank Co.,Ltd. Pledgor: NANJING HUASHI NEW MATERIAL Co.,Ltd. Registration number: Y2024980010726 |